Conflict of Interest in MS Drug Trials Matters to Participants

Share this content:
Conflict of Interest in MS Drug Trials Matters to Participants
Conflict of Interest in MS Drug Trials Matters to Participants

HealthDay News — Disclosure of physician-industry relationships is an important and possibly participation-altering factor in multiple sclerosis clinical trials, according to a study published in the Multiple Sclerosis Journal.

Andrew J. Solomon, MD, from the University of Vermont College of Medicine, and colleagues used an anonymous online instrument to examine attitudes of 597 patients with multiple sclerosis concerning disclosure of potential physician-industry conflicts of interest created by clinical trials. The authors further assessed the impact of disclosure of these conflicts of interest on study participation.

The researchers found that detailed disclosure of conflicts of interest was important for potential participants in industry-sponsored trials for multiple sclerosis therapies. The presence of these conflicts might influence patient participation in these trials.

"Findings from this study support a call for uniform guidelines regarding disclosure of physician-industry relationships to prospective research participants for industry-sponsored clinical trials," the authors write.

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.

Reference

  1. Solomon AJ et al. Mult Scler. 2015; doi:10.1177/1352458515569101.
You must be a registered member of Neurology Advisor to post a comment.

Sign Up for Free e-newsletters

CME Focus